Pegylated interferon and ribavirin therapy for hepatitis C causing cataract

Clinical and Experimental Ophthalmology

Volumn 37, Issue 7, 2009, Pages 743-745

  Ku, Jae Yee ^a   Sharma, Anil ^b  

^a SYDNEY EYE HOSPITAL   (Australia)

^b Mater Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ANTERIOR EYE SEGMENT; CASE REPORT; CATARACT; CONJUNCTIVITIS; EYE REFRACTION; HEPATITIS C; HUMAN; INTRAOCULAR PRESSURE; LETTER; MALE; OPHTHALMOSCOPY; PERIMETRY; PHYSICAL EXAMINATION; REFRACTION ERROR; SYMPTOMATOLOGY; VISUAL ACUITY;

ANTIVIRAL AGENTS; CATARACT; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LENS, CRYSTALLINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; VISUAL ACUITY;

EID: 70350162091     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02125.x     Document Type: Letter

References (5)

1. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in australia. J Clin Virol 2003, 26:171-84.
2. Schulman JA, Liang C, Kooragayala LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmol 2003, 110:437-42.
3. Farel C, Suzman DL, McLaughlin M. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2a and ribavirin. AIDS 2004, 18:1805-9.
4. d'Alteroche L, Majzoub S, Lecuyer A, Delplace M, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006, 44:56-61.
5. Ahmed F, Jacobson IM, Chen ST. Serious ophthalmologic events during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial. Hepatology 2003, 38:734A-5A.